{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:25:48Z","timestamp":1793413548846,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":914,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/jto.0b013e31828c7210","type":"journal-article","created":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T04:03:54Z","timestamp":1365653034000},"page":"693-702","source":"Crossref","is-referenced-by-count":114,"title":["The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib"],"prefix":"10.1016","volume":"8","author":[{"given":"Yiyu","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-He","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Perez-Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Piperdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31828c7210_bib1","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor receptor kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c7210_bib2","first-page":"739","article-title":"Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice","volume":"291","author":"Pollack","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1097\/JTO.0b013e31828c7210_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e31828c7210_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib5","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"12 Pt 2","key":"10.1097\/JTO.0b013e31828c7210_bib6","doi-asserted-by":"crossref","first-page":"4238s","DOI":"10.1158\/1078-0432.CCR-040017","article-title":"The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer","volume":"10","author":"Perez-Soler","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c7210_bib7","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1097\/JTO.0b013e31828c7210_bib8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc1692","article-title":"The role of autophagy in cancer development and response to therapy","volume":"5","author":"Kondo","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1097\/JTO.0b013e31828c7210_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cell.2004.11.046","article-title":"Growth factor regulation of autophagy and cell survival in the absence of apoptosis","volume":"120","author":"Lum","year":"2005","journal-title":"Cell"},{"key":"10.1097\/JTO.0b013e31828c7210_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrm2239","article-title":"Self-eating and self-killing: crosstalk between autophagy and apoptosis","volume":"8","author":"Maiuri","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Suppl 2","key":"10.1097\/JTO.0b013e31828c7210_bib11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/sj.cdd.4401751","article-title":"Autophagy and signaling: their role in cell survival and cell death","volume":"12","author":"Codogno","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1097\/JTO.0b013e31828c7210_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/mol.107.034827","article-title":"Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1\/S phase arrest in human non-small-cell lung cancer cell lines","volume":"72","author":"Ling","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1124\/mol.107.044396","article-title":"Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK","volume":"74","author":"Ling","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ijc.21290","article-title":"Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells","volume":"118","author":"Janmaat","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e31828c7210_bib15","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1158\/0008-5472.CAN-04-1905","article-title":"Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255","volume":"64","author":"Tracy","year":"2004","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c7210_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/JTO.0b013e3181753b24","article-title":"Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene","volume":"3","author":"Li","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib17","first-page":"3","article-title":"Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles","volume":"66","author":"Biederbick","year":"1995","journal-title":"Eur J Cell Biol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2010.01.028","article-title":"Methods in mammalian autophagy research","volume":"140","author":"Mizushima","year":"2010","journal-title":"Cell"},{"key":"10.1097\/JTO.0b013e31828c7210_bib19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1083\/jcb.200907014","article-title":"Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes","volume":"186","author":"Simonsen","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1083\/jcb.90.3.665","article-title":"Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages","volume":"90","author":"Poole","year":"1981","journal-title":"J Cell Biol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1097\/JTO.0b013e31828c7210_bib22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3816\/CLC.2007.n.041","article-title":"Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation","volume":"8","author":"Mahaffey","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e31828c7210_bib23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1471-2407-10-370","article-title":"Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells","volume":"10","author":"Sasaki","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1097\/JTO.0b013e31828c7210_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.lba7501","article-title":"TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR","volume":"30","author":"Garassino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1097\/JTO.0b013e31828c7210_bib26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/2159-8290.CD-11-0106","article-title":"BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors","volume":"1","author":"Faber","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1097\/JTO.0b013e31828c7210_bib27","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations","volume":"68","author":"Yano","year":"2008","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c7210_bib28","doi-asserted-by":"crossref","first-page":"e18691","DOI":"10.1371\/journal.pone.0018691","article-title":"EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells","volume":"6","author":"Han","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1097\/JTO.0b013e31828c7210_bib29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4161\/cbt.11.12.15693","article-title":"Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death","volume":"11","author":"Eimer","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1097\/JTO.0b013e31828c7210_bib30","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10637-009-9380-z","article-title":"Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)","volume":"29","author":"Tran","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1097\/JTO.0b013e31828c7210_bib32","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1097\/JTO.0b013e318262de4a","article-title":"A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer","volume":"7","author":"Goldberg","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1535-7163.465.3.4","article-title":"Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor\/extracellular signal-regulated kinase \u00bd and EGF receptor\/Akt pathway for proliferation","volume":"3","author":"Ono","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1097\/JTO.0b013e31828c7210_bib34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejphar.2009.06.063","article-title":"Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies","volume":"625","author":"Solomon","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1097\/JTO.0b013e31828c7210_bib35","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1097\/JTO.0b013e31828c7210_bib36","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1158\/1078-0432.CCR-11-0816","article-title":"Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation","volume":"17","author":"Ding","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31828c7210_bib37","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/art.10307","article-title":"Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis","volume":"46","author":"Munster","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1097\/JTO.0b013e31828c7210_bib38","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMe0905763","article-title":"Personalized medicine and inhibition of EGFR signaling in lung cancer","volume":"361","author":"Gazdar","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415328434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415328434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T19:25:46Z","timestamp":1688153146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415328434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1556086415328434"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31828c7210","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717999509.793503137","asserted-by":"object"}]},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}